Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026)
Table of Contents
- The same trick, a different tool
- Block the recycling, lose the antibodies
- Myasthenia gravis, with a broader door
- The part that makes it different: it goes everywhere
- Into the womb: treating a fetus by dosing the mother
- The newest headline: warm autoimmune hemolytic anemia
- A platform, and the same caveats
The same trick, a different tool
Yesterday's entry, efgartigimod, introduced the idea of blocking FcRn - the receptor that rescues your antibodies from destruction and recycles them back into the blood. Nipocalimab does exactly that, but with a different molecule. Efgartigimod is a snipped-out fragment of an antibody, the small Fc tail that grabs FcRn. Nipocalimab is a whole, full-length monoclonal antibody, engineered so its only job is to sit on FcRn. Johnson & Johnson built it to be 'aglycosylated' - stripped of the sugar on its tail that normally lets an antibody call in immune firepower - so it is 'effectorless': it occupies the receptor without triggering the collateral immune reactions a normal antibody would. Same target, same consequence, different design.
Block the recycling, lose the antibodies
The downstream effect mirrors efgartigimod. When nipocalimab saturates FcRn, circulating IgG that would normally be caught and returned to the bloodstream is instead sent to the lysosome and broken down. Total IgG falls by roughly 65 to 75 percent with continued dosing, and because pathogenic autoantibodies are just IgG, they drop along with the rest - while IgM, IgA, complement, and albumin, which do not rely on FcRn, are left essentially untouched. The main difference in rhythm: nipocalimab is given as a maintenance intravenous infusion aimed at keeping IgG down continuously, rather than efgartigimod's short 'reduce and recover' cycles. It is one of the cleaner natural experiments in modern drug design - two molecules, one target, different formats and schedules.
Myasthenia gravis, with a broader door
Nipocalimab's first approval came in the same disease that launched efgartigimod: generalized myasthenia gravis, where antibodies jam the signal between nerve and muscle. In the Phase 3 Vivacity-MG3 trial, nipocalimab plus standard care produced a statistically significant, sustained improvement in the MG-ADL daily-living score over weeks 22 to 24 versus placebo plus standard care - a design built to show durable control rather than a one-week blip. The FDA approved Imaavy on April 30, 2025, and the label was notably wide: it covers both AChR- and MuSK-antibody-positive patients and reaches down to age 12, making nipocalimab the first FcRn blocker cleared for adolescents and the first to explicitly include MuSK-positive disease.
The part that makes it different: it goes everywhere
Where nipocalimab really separates from the pack is breadth. In the Phase 2 DAHLIAS trial in moderate-to-severe Sjogren's disease - a condition with almost no effective systemic drugs - nipocalimab hit its primary endpoint, significantly improving the ClinESSDAI disease-activity score at 24 weeks, with patients also reporting less dryness and pain. That earned Breakthrough Therapy and Fast Track designations and a publication in The Lancet. It has shown activity in rheumatoid arthritis, and in January 2026 it picked up Fast Track designation for lupus. Johnson & Johnson is effectively testing whether one FcRn blocker can serve neurology, rheumatology, and hematology at once.
Into the womb: treating a fetus by dosing the mother
The most striking use of nipocalimab has nothing to do with adults. FcRn is also the receptor that ferries a mother's antibodies across the placenta to her baby - useful when those antibodies are protective, dangerous when they attack the fetus's own blood cells, as in hemolytic disease of the fetus and newborn (HDFN). Because nipocalimab blocks that same transporter, dosing the mother can reduce how much harmful antibody reaches the fetus. In the Phase 2 UNITY study of pregnancies at high risk of early-onset severe HDFN, 54 percent of treated women reached a live birth at or after 32 weeks without a single intrauterine transfusion - a dramatic result in a group that historically faces repeated in-utero procedures. It was published in the New England Journal of Medicine, is now being confirmed in the Phase 3 AZALEA trial, and has a sibling program in fetal and neonatal alloimmune thrombocytopenia (FNAIT). No other FcRn blocker is being developed this way.
The newest headline: warm autoimmune hemolytic anemia
The reason nipocalimab is back in the news in 2026 is warm autoimmune hemolytic anemia (wAIHA), a disease in which IgG antibodies coat red blood cells and mark them for destruction. Lowering IgG is a direct fit for the mechanism, and on April 27, 2026 the FDA granted Priority Review to nipocalimab for wAIHA on the strength of the placebo-controlled ENERGY trial - which, if approved, would make it the first therapy specifically cleared for the condition. It is another instance of the same logic: find a disease driven by IgG autoantibodies, and lower the IgG.
A platform, and the same caveats
Nipocalimab is best understood not as a single-disease drug but as a bet that FcRn blockade is a platform - one molecule aimed at myasthenia gravis, Sjogren's, lupus, hemolytic anemia, and maternal-fetal disease. The caveats are the class caveats. Cutting IgG by two-thirds or more raises infection risk, and infections, headache, and infusion reactions were among the most common adverse events; the long-term effects of sustained IgG lowering, including on vaccine responses and - in pregnancy - on the newborn's own immunity, are still being mapped. And like every FcRn blocker, it does nothing for diseases not driven by IgG. But alongside efgartigimod, nipocalimab has turned FcRn from a textbook curiosity into one of the most versatile targets in autoimmune medicine, and it is the benchmark the newer blockers rozanolixizumab and batoclimab now have to beat.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Johnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis - Johnson & Johnson, April 2025 Source
- [2] FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis (Vivacity-MG3) - NeurologyLive Source
- [3] Efficacy and safety of nipocalimab in moderate-to-severe Sjogren's disease (DAHLIAS) - The Lancet, 2025 Source
- [4] Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (UNITY) - New England Journal of Medicine, 2024 Source
- [5] FDA grants Priority Review for IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) - Johnson & Johnson, April 2026 Source
- [6] Nipocalimab (M281): mechanism, identifiers, indications - DrugBank DB16257 Source
Related Articles
Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)
Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.
Efzofitimod: A First-in-Class Immunomodulatory Peptide Aims to Take Sarcoidosis Patients Off Steroids (July 1, 2026)
Efzofitimod (ATYR1923) is a first-in-class immunomodulatory peptide that binds neuropilin-2 to calm lung inflammation in pulmonary sarcoidosis. Its Phase 3 EFZO-FIT trial missed its primary steroid-reduction endpoint in 2025 but showed benefit on symptoms and lung function — here is what it is, how it works, and where it stands in 2026.
Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026)
Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.